The following table summarizes the fair values of the assets acquired and liabilities assumed on July 31, 2015 (in thousands of euros):
|
In process research and development |
|
17,374 |
|
|
Accounts receivable (received from Genetrix) |
|
3,306 |
|
|
Other net asset acquired: |
|
|
|
|
Other intangible assets |
|
277 |
|
|
Property, plant and equipment |
|
109 |
|
|
Other current assets |
|
1,310 |
|
|
Cash |
|
3 |
|
|
Financial Loans |
|
(3,870 |
) |
|
Trade & other payables |
|
(635 |
) |
|
|
|
|
|
|
|
|
|
|
|
Total Net Asset Acquired |
|
17,874 |
|
|
|
|
|
|
|
|
|
|
|
|
Total Consideration |
|
18,591 |
|
|
|
|
|
|
|
|
|
|
|
|
Goodwill on acquisition |
|
717 |
|
|
|
|
|
|
|
|
|
|
|
Total consideration of the business combination is broken down as follows (in thousand of euros):
|
Cash consideration payable |
|
1,154 |
|
|
Issuance of ordinary shares of TiGenix, N.V. according to the Contribution Agreement |
|
6,093 |
|
|
Estimated fair value of contingent consideration |
|
11,344 |
|
|
|
|
|
|
|
|
|
|
|
|
Total Purchase Price |
|
18,591 |
|